Transplantation, 5, 1273; Currie and Bagshawe, 1968, Br. J. Cancer, 22, 588) . This is interpreted as being due to modification of cell surfaces, by removal of sialic acid and/or permanent binding of enzyme molecules, increasing tumour-cell immunogenicity (Rios 31 and Simmons, 1974, Int. J. Cancer, 13, 71; Sedlacek and Seiler, 1974, Behring Inst. Mitt., 55, 254) . Other workers have failed to confirm these findings, and ascribe them only to nonspecific toxicity (Yuhas et al., 1974, J. natn. Cancer Inst., 53, 665; Froese et al., 1974, J. natn. Cancer Inst., 52, 1905) . In the present tests, the influence of Vibrio cholerae neuraminidase (VCN) (Behringwerke) on the growth of a range of rat tumours has been examined. In vitro incubation under standard conditions (5-25 units/106 cells, 30 min, 37°C at pH 5-6) released 0-2-1-0 jumol sialic acid/109 cells, but consistently failed to reduce their in vivo tumorigenicity. With all of 7 tumours examined (sarcomas, hepatoma, mammary carcinoma and epithelioma) incidences and growth rates were identical to those from untreated cells and/or cells exposed to only pH [5] [6] Cell preparations with high viability and low host-cell contamination have been prepared from human tumour biopsies and used as targets in 5lCr-release cytotoxicity assays. Autologous lymphocytes from blood and, when possible, from the draining lymph node and within the tumour were used as effectors. Significant reactivity was determined in 11/30 blood lymphocytes. Tests with 4 benign conditions were negative. Reactivity in the draining lymph node largely paralleled that in the blood, but tumour-infiltrating lymphocytes were generally non-reactive against autologous biopsy cells although responses to PHA and in MLC were detectable. Cytotoxicity against K562 (a long-term culture line known to be sensitive to natural killer activity) was frequently detected in blood lymphocytes but only rarely in the lymph node and tumour lymphocytes. Similar patterns of reactivity were detected when the autologous tumour stimulation assay was used. Increased uptake of 3H-thymidine following exposure to autologous biopsy cells was revealed in 6/11 blood preparations 7/10 lymph nodes and 1/7 tumour-infiltrating lymphocytes. Cross-reactivity between foetal antigens and antigens of malignant cells has been reported in human lung cancer (Bell, 1976, Cancer, 37, 706) . In this study an antiserum was raised to human foetal lung and extensively absorbed to remove haemagglutinating, haemolytic, lymphocytotoxic and antiplatelet antibodies. Sequential absorptions with human spleen and thymus were monitored by lymphocytotoxicity and immunofluorescence with human peripheral-blood lymphocytes. The unabsorbed and 4 x absorbed samples were widely cross-reactive with human lung cancers, foetal and adult normal tissues. However, the 9 x absorbed serum, negative with lymphocytes by both cytotoxicity and immunofluorescence, selectively Plasma samples from patients undergoing simple mastectomy for primary breast carcinoma were tested for immune complexes by a modified Clq-binding assay (Zubler et al., 1976, J. Immunol., 116, 232) . Tests were performed on samples taken preoperatively and 12 months postoperatively from three groups of patients: a group having no tumour detectable histopathologically in the axillary or internal mammary lymph nodes (good prognosis); a group having tumour detected in nodes from the apex of the axilla or internal mammary chain (poor prognosis); and a small group ofpatients dying within 22 months of mastectomy. Preoperative samples from all three groups of patients gave significantly higher Clq binding than in control samples from normal age-matched women. Moreover, post-mastectomy samples from good-prognosis patients were in the normal range, whereas samples from poor-prognosis patients and those with a short survival remained significantly elevated after mastectomy. It has been proposed that the mechanism of action in vivo of dimethyltriazenes may involve their metabolic N-demethylation to monomethyltriazenes (which are alkylating agents) since monomethyltriazenes are cytotoxic in vitro whereas dimethyltriazenes are not (Connors et al., 1976 Biochem. Pharmac. 25, 241) . However, there is some evidence which suggests that the dimethyltriazenes may not owe their activity in vivo to the formation of an alkylating agent; for example they are active against a tumour which is naturally resistant to alkylating agents (Connors and Hare, 1975 Biochem. Pharnac. 24, 2133) . Using a bioassay system we have compared the cytotoxicity of a monomethyltriazene to TLX5 cells and TLX5/R cells (which have had resistance to dimethyltriazenes induced in vivo) and found no difference between them. The cytotoxicity of a monoethyltriazene was found to be of the same order as for the monomethyl, although the diethyltriazenes have no in vivo antitumour effect, despite undergoing N-deethylation. The results suggest that monoalkyltriazenes are nonselective cytotoxic agents.
IMMUNOLOGICAL

COENZYMES AND TUMOUR CHEMO-THERAPY BY ALKYLATING AGENTS.
R. SCHOENTAL, Royal Veterinary College, London.
Tumour chemotherapy is often bedevilled by the unexplained variability of response of individual patients to any schedule of treatment, even when the tumour characteristics appear to be similar. In the case of alkylating agents this may be due to the nutritional status of the patient, especially to the levels of B vitamins and of the various forms of coenzymes (such as NAD, FAD, CoA, folates, etc) which on alkylation of their reactive nucleophilic groups become inactivated, so that the respective enzymes are no longer able to exert their vital biochemical functions (compare: Schoental, 1976, FEBS Letters, 61, 111; Schoental and Cavanagh, 1977, Neuropath. Appl. Neurobiol., 3, 145; Schoental, 1977 , Biochem. Soc. Trans., 5, 1016 A recently developed staining technique using acridine orange enables RNA and DNA to be estimated simultaneously in individual cells (Traganos et al., 1977, J. Histochem. Cytochem., 25, 46) . These methods have been used in vivo to demonstrate that the RNA content in a "more" clonogenic fraction of EMT6 mouse tumour cells, separated by the method of Twentyman and Watson, 1977 (Br. J. Cancer, 35, 120 ) is higher than in a "less" clonogenic fraction. In vitro studies have shown that the RNA content of exponentially growing EMT6 cells is higher than that of late-plateau cells. Following mitotic-selection synchronization we have found that the RNA levels increase during GI, but remain virtually constant in early and mid S. However, a second rapid increase in RNA levels occurs during late S. These results were parallelled by changes in the rate of 3H-UdR uptake as measured by autoradiography. Methodology has been established for the specific assay of the hypoxic cell sensitizer Misonidazole
STUDIES ON THE PHARMACOKINE-TICS OF MISONIDAZOLE (Ro
(1-(2-nitroimidazol-1-yl)-3-methoxypropan-2-ol; Ro 07-0582) and its 0-demethylated metabolite (1-(2-nitroimidazol-1-yl)-2,3-propandiol; Ro 05-9963) in biological materials, using reverse-phase highpressure liquid chromatography (HPLC).
In 10 patients with malignant disease receiving 3 g/m2 Misonidazole orally, typical plasma levels of 120 ,tg/ml were observed 1-4 h after administration. Tumour levels estimated in a patient with carcinoma of the breast were in the range 50-70% of the corresponding plasma values. Concentrations of Ro 05-9963 in plasma and tumour were normally .10% of those of the parent drug.
Radiotherapy was given at 4 h and significant radiation enhancement ratios would be expected under these conditions. A rapid-distribution phase (ti = 28-7-2 min, mean 5`5 min), was followed by a slower phase, (tl -6-9-218 min, mean 12-5 min) representing metabolism and excretion. The apparent volume of distribution of 5-FU at time zero ranged from 4 0 to 21-8 1, reflecting individual differences in the extent of absorption of the drug by tissues. A second peak appeared in GLC elution profiles of plasma extracts within 15 min of drug administration. The vitamin A compounds examined were retinol, retinoic acid and 9 of its structural analogues synthesized in an attempt to increase the anti-carcinogenic activity and to lower the toxicity of their parent compound. These included the cyclopentenyl analogue of retinoic acid, a-retinoic acid,-A2-retinoic acid, 13cis cx-retinoic acid and 6 aromatic analogues.
The compounds were either added to the culture medium simultaneously with methylcholanthrene or administered to explants which had been pretreated with the carcinogen.
If combined with the carcinogen, the compounds inhibited the hyperplasia to a striking degree; if applied following exposure to the carcinogen they reversed epithelial hyperplasia and metaplasia and largely restored a normal pattern of growth.
The inhibitory effect of most of the analogues was similar to or greater than that of their parent compound, and seemed to be caused by a reduction of DNA synthesis. The effect was not due to a reduced uptake or increased release of the carcinogen by the vitamin-A-treated tissue. It also appeared unrelated to the biological growth-promoting activity of the compounds or their surfaceactive properties. (Lasnitzki, 1976, Br. J. Cancer, 34, 239 ) and the present study was undertaken to assess the toxicity of these compounds towards tissues by measuring the degradation of cartilage in vitro.
The release of 3584-from pre-labelled rabbit ear cartilage in the presence of 19 retinoids wAas measured by a method previously described (Bard and Lasnitzki, 1977, Br. J. Cancer, 35, 115) . Compounds retaining a carboxylic-acid group were found to be most active in releasing sulphate, whereas esters, substituted amides and ethers caused much less breakdown of the tissue. Alteration of the molecule from the 13-trans to the 13-cis configuration and several modifications of the hexenyl ring had little effect on the activity towards cartilage. The combination of moderate hyperthermia (43°C water bath for 1 h) and 1,3 Bis (2-chloroethyl)-l-nitrosourea against the EMT6 mouse tumour has been studied. The effect was found to be much greater than would have been predicted from the effects of the single modalities, and this is true whether the end point be tumour cure, growth delay, or in vitro assay of clonogenic fraction. The results indicate that inhibition of "recovery from potentially lethal drug damage" is not the mechanism by which heat potentiates the action of BCNU. 
IDENTIFICATION OF PATHOGENIC
GRANT and G. GETTINBY, Royal Infirmary
and Universities of Glasgow and Strathclyde, Glasgow. Striking differences in chemotherapyrelated delay of recrudescence of mammary cancers in premenopausal and in postmenopausal women have been described in two recent trials (Fisher et al., 1975, New Engl. J. Med., 292, 117 ; Bonadonna, Symposium of British Association of Surgical Oncology, Dec. 17, 1976) . The longer cancer-free interval in premenopausal women may result from direct or pituitary-mediated suppression of ovarian functions. However, no significant differences in plasma oestradiol and androgens at both follicular and luteal phases have been observed in 6 node-positive patients menstruating regularly, during monthly 5-day pulses of oral melphalan. The differences between follicular and luteal levels of oestradiol were, as expected, statistically significant (P< 0.05) in a Mann-Whitney U test, confirming the need to study putative chemotherapeutic effects at these phases separately.
Unexpectedly, plasma oestradiol levels were lower after similar pulses of melphalan in 6 node-positive postmenopausal patients (P < 0 05 in Mann-Whitney U test) indicating that, although steroid hormones may be influenced by melphalan, an uncomplicated suppression of premenopausal ovaries is not the only factor worthy of investigation.
MODULATION OF ALKYLATING
AGENT TOXICITY AND ANTITUM-OUR EFFECT BY STEROIDS. R. WIL-KINSON and K. R. HARRAP, Inst. of Cancer Res., Sutton, Surrey. Prednisolone is frequently included in clinical treatment schedules with alkylating agents, where tumouricidal effects could be expected from both components. We have previously shown, however, that predniisolone in combination with chlorambucil potentiates cytotoxicity against cells in which prednisolone alone has no effect (Harrap et al., 1977, Eur. J. Cancer, 13 . More recent studies indicate that prednisolone may be combined with other alkylating agents with beneficial effects. By combining prednisolone with nitrogen mustard it is possible to suppress the toxicity of the alkylating agent, whilst enhancing its antitumour effect. In the case of binary combinations of melphalan and prednisolone, both toxicity and antitumour effect are increased above those of the alkylating agent alone. These effects are closely dependent upon schedule design and, by administering the steroid after the alkylating agent, toxicity can be reduced with no loss of antitumour effect. In sensitive cells, alkylating agent cytotoxicity is accompanied by morphological dissociation of chromatin and changes in nuclear protein integrity, which are not detected in resistant cells. However, Using an in vitro toad system, described by Jones and Jackson (1974, J. Reprod. Fertil., 38, 347) Prednisolone intramuscularly (4 cases) and orally (2 cases) for 5 weeks, was shown to improve vigour and appetite, red-cell picture, neutrophil and platelet counts. Circulating tumour-cell counts and lymph-node size were reduced to normal. Relapse occurred 5 weeks after withdrawal of the drug. One 18-month-old pig was treated for 2 months with prednisolone and improved dramatically, but after another 2 months became recumbent and refused to eat. Autopsy showed a lymphomatous mass in the meninges pressing on the brain. Tumour has not been seen at this site in any of 50 untreated cases, and it provides a good analogy to lymphocytic leukaemia in children. An almost moribund 4-month-old female improved on treatment with prednisolone, followed by vincristine and cyclophosphamide. The last two drugs given 48 h apart showed better results than when given simultaneously. Remission was maintained for over a year and the pig looked normal. Although adriamycin is not reported to be an effective single agent, the above combination certainly produced a higher response rate than that reported from conventional chemotherapy in advanced malignant melanoma. Further work will be aimed at defining the active drugs in the combination. In conclusion the combination of adriamycin, cyclophosphamide, vincristine and prednisolone produced 6/10 partial responses compared to 1/14 using conventional therapy with DTIC, Razoxane has shown actively in acute lymphoblastic and in acute myeloblastic leukaemia (AML) of children (Hellmann et al., 1969, Brit: med. J., i, 822; Krepler and Pawlowsky, 1975, Osterreichische Z. Onkol., 2, 112) . Since AML has a particularly poor prognosis in the elderly, and because treatment of this group of patients presents considerable problems, razoxane was combined with cytosine arabinoside (the mainstay of AML treatment). The regime consisted of razoxane 125 mg 3 x daily for 3 days and Ara-C 1 mg/kg i.v. on the same 3 days. The course was repeated every 5-7 days. Toxicity, if any, was chiefly haematological, but when normal blood elements declined, they began to recuperate after a few days. Of 5 patients with acute monocytic or myelomonocytic leukaemia, 1 did not respond, 3 had partial remissions and 1 had a complete remission. The regime is suitable for outpatient administration and no special nursing care is required. Supportive care required when patients were in hospital was minimal. A striking feature of the response in 3 of the patients was the rapidity of onset of the blast clearance of the blood. From wNhat is known of the clinical activity of the two drugs it would be most unlikely that the results so far could have been obtained with either of the drugs alone, but whether they potentiate each other or are merely good additive agents is not known as yet. 
